Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma

Single dose of etokimab resulted in rapid and sustained lung function improvement and ACQ-5 score reduction through at least Day 64 Etokimab was well tolerated and no serious adverse events were reported Data supports infrequent dosing of etokimab in the treatment of eosinophilic asthma, which is

AnaptysBio to Present at the Jefferies 2019 Healthcare Conference

SAN DIEGO , May 28, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates

Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019 Etokimab Phase 2a Severe Eosinophilic Asthma Data to be Presented at the 2019 EAACI Congress IND Filing for New Wholly-owned Anti-inflammatory Program Anticipated in Second Half of 2019 SAN DIEGO ,